SCHEMBL5897137

SCHEMBL5897137

[CH2]NCCN1CCN(C)CC1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 2/20 0.41
PRMT6 Q96LA8 2/20 0.41
PRMT8 Q9NR22 2/20 0.41
HDAC2 Q92769 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
ACE2 Q9BYF1 1/20 0.39
KDM1A O60341 1/20 0.38
CNR1 P21554 1/20 0.37
PAOX Q6QHF9 1/20 0.36
PRMT1 Q99873 1/20 0.35
KAT2B Q92831 1/20 0.35
MC4R P32245 1/20 0.34
SIGMAR1 Q99720 4/20 0.34
ALDH1A1 P00352 1/20 0.33
PGK1 P00558 1/20 0.33
POLB P06746 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4760025 0.86 PAOX (0.42) ACE2PAOXSIGMAR1ALDH1A1
SCHEMBL2076864 0.79
SCHEMBL4395015 0.79 ACE2 (0.61) CARM1PRMT6PRMT8HDAC2HDAC8
SCHEMBL2281455 0.77 CARM1 (0.68) CARM1PRMT6PRMT8HDAC2HDAC8
SCHEMBL12829261 0.77 CARM1 (0.68) CARM1PRMT6PRMT8HDAC2HDAC8
SCHEMBL2077311 0.77 CARM1 (0.54) CARM1PRMT6PRMT8SIGMAR1ALDH1A1
SCHEMBL10764316 0.75 ACE2 (0.44) CARM1PRMT6PRMT8HDAC2HDAC8
SCHEMBL19966100 0.75 CARM1 (0.41) CARM1PRMT6PRMT8HDAC2HDAC8
SCHEMBL20687972 0.75 CARM1 (0.37) CARM1PRMT6PRMT8HDAC2HDAC8
SCHEMBL6143515 0.74 PAOX (0.46) KDM1APAOXMC4RSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7060700-B2 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB (SE) 2006-06-13 US claimed
CN-1142912-C Amide derivs. useful as inhibitors of production of cytokines 2004-03-24 CN claimed
US-20030105142-A1 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB 2003-06-05 US claimed
US-6432949-B1 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB (SE) 2002-08-13 US claimed
CN-1321150-A Amide derivs. useful as inhibitors of production of cytokines ASTRAZENECA AB (SE) 2001-11-07 CN claimed
US-7060700-B2 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB (SE) 2006-06-13 US disclosed
CN-1142912-C Amide derivs. useful as inhibitors of production of cytokines 2004-03-24 CN disclosed
US-20030105142-A1 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB 2003-06-05 US disclosed
US-6432949-B1 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB (SE) 2002-08-13 US disclosed
CN-1321150-A Amide derivs. useful as inhibitors of production of cytokines ASTRAZENECA AB (SE) 2001-11-07 CN disclosed
EP-1102750-A1 AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES AstraZeneca AB (SE) 2001-05-30 EP disclosed
WO-2000007991-A1 AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES ASTRAZENECA AB (SE) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105142-A1 Amide derivatives useful as inhibitors of the production of cytokines IL6, IL6ST, IL2 CARM1 3436/4885PRMT6 1007/4885PRMT8 2556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.